Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Adia Nutrition, Inc.

Ticker
ADIA
Sector
Industry
Report date
November 16, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news coverage includes broad market and sector developments but no company-specific announcements. The company’s latest SEC filing provides updated financial data as of Q3 2026.

Recent developments:
  • The company’s latest 10-Q filing dated November 16, 2026, reports Q3 2026 revenue of $454,385 and a net loss of $53,015, with cash and equivalents of $1,137,818 and a current ratio of 1.09 [S2].
  • Adia Nutrition continues to operate in the regenerative medicine sector focusing on stem cell therapies and biologic products [S1].
  • Recent news articles cover general market events such as Nvidia earnings and Fed minutes but do not mention Adia Nutrition specifically [N1].
Overview

Adia Nutrition, Inc. operates in the biotechnology and regenerative medicine sector, specializing in Autologous Hematopoietic Stem Cell Transplantation (AHSCT) and umbilical cord stem cell therapies. The company runs medical clinics (Adia Med) and a laboratory (Adia Labs) that produce and distribute biologic products such as AdiaVita and AdiaLink. These products are designed to address orthopedic, pain management, wound repair, anti-aging, and tissue repair needs. The company’s operations comply with FDA regulations under Section 361 of the Public Health Service Act and maintain accreditation from the American Association of Tissue Banks (AATB). Adia Nutrition also holds an equity stake in a supplement company, Cement Factory, LLC, focusing on organic supplements sold direct-to-consumer. The company transitioned from a shell company to an operating business in 2024 through acquisitions and business model execution. Financially, as of Q3 2026, the company reported revenues of $454,385 and a net loss of $53,015, with liquidity ratios indicating a current ratio of 1.09 and a cash ratio of 0.79.

Executive summary

Adia Nutrition, Inc. is a regenerative medicine company focused on stem cell therapies and biologic products, operating medical clinics and labs in the U.S. The company transitioned from a shell to an operating entity in 2024, acquiring assets and beginning revenue generation. Its products are FDA registered under Section 361 of the PHSA and the company complies with relevant regulatory standards. Financial data as of Q3 2026 shows modest revenue with a net loss and liquidity ratios indicating near parity of current assets to liabilities. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for ADIA

Bull case model:

The company’s establishment of FDA-registered and AATB-accredited manufacturing facilities, combined with trademarked products and a growing network of clinics, supports its ability to deliver regenerative medicine therapies. The expanding stem cell therapy market and easing regulatory environment in key states like Florida provide opportunities for broader geographic expansion. Strategic equity investments in the supplement sector diversify revenue streams and enhance brand portfolio. The company’s vertical integration and focus on standardized stem cell protocols with FDA-approved labs may strengthen its competitive position.

Bear case model:

Adia Nutrition operates in a competitive and moderately fragmented market with numerous small competitors, some of which may consolidate or exit due to funding challenges. The company reported a net loss in Q3 2026 and has liquidity ratios close to parity, indicating limited financial cushion. Regulatory changes could impose additional compliance costs or restrict operations. The company’s reliance on evolving FDA regulations and the need for ongoing accreditation and quality control present operational risks. Market acceptance and reimbursement for stem cell therapies remain uncertain, and competition from pharmaceutical companies entering regenerative medicine could intensify.

Moat:

Adia Nutrition’s moat is based on its FDA-registered biologic products compliant with Section 361 of the PHSA, its AATB-accredited laboratory, and its proprietary trademarks and provisional patent filings. The company’s integration of clinical operations with product manufacturing and distribution provides a vertically aligned business model. Its focus on regenerative medicine and stem cell therapies positions it in a specialized and growing market segment with regulatory barriers that may limit new entrants. However, the market is moderately fragmented with 30 to 50 competitors, and the company faces potential future competition from pharmaceutical firms entering regenerative medicine.

Risks overview
Risks summary
Regulatory compliance and financial sustainability are the primary risks facing Adia Nutrition, given the evolving regulatory environment and the company's current net losses and liquidity position.
Risks details:

• Regulatory Risk: The company operates under FDA regulations for Section 361 HCT/Ps and must maintain compliance with evolving federal and state requirements. Changes in regulatory standards or delays in approvals could impact operations.
• Financial Risk: Reported net losses and liquidity ratios near 1.0 indicate limited financial flexibility. The company may face challenges funding growth or sustaining operations without additional capital.
• Market Competition: The regenerative medicine market is moderately fragmented with many competitors. Potential entry by large pharmaceutical companies could increase competitive pressures.
• Operational Risk: Maintaining FDA registration, AATB accreditation, and quality control requires ongoing investment and operational discipline. Failure to meet standards could affect product availability and reputation.

FINAL FORECAST FOR ADIA

Final take one line
Adia Nutrition, Inc. is a regenerative medicine company with detailed SEC disclosures and recent financial data, operating in a growing but competitive stem cell therapy market.
Final take 12 to 24 month view

Business trends: Expansion of stem cell therapies and regenerative medicine with increasing regulatory clarity and market acceptance.
Execution milestones: Transition from shell to operating company, acquisition of Biolete LLC, establishment of FDA-registered labs and clinics, and trademarking of key products.
Key risks: Regulatory compliance challenges, financial sustainability amid net losses, competitive pressures from fragmented market and potential pharmaceutical entrants.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Adia Nutrition, Inc. is a Nevada corporation originally incorporated in 1975 and underwent several name changes before adopting its current name in 2012.
  • The company was previously a shell company but changed control and merged operations on January 22, 2024, acquiring Biolete LLC and becoming a non-shell company as of June 30, 2024.
  • Adia Nutrition operates in the regenerative medicine sector focusing on Autologous Hematopoietic Stem Cell Transplantation (AHSCT) and umbilical cord stem cell therapies.
  • The company operates medical clinics (Adia Med) and a laboratory (Adia Labs) that produces biologic products such as AdiaVita and AdiaLink, which are trademarked and designed for regenerative medicine applications.
  • AdiaVita is an umbilical cord stem cell product registered with the FDA under section 361 of the Public Health Service Act, containing at least 100 million stem cells and 3 trillion exosomes per unit.
  • AdiaLink is an exosome product derived from human amniotic fluid, intended for clinical studies and research.
  • The company’s products address orthopedic issues, pain management, wound repair, anti-aging, and tissue repair.
  • Adia Nutrition’s laboratory is FDA registered and accredited by the American Association of Tissue Banks (AATB), complying with cGMP and ISO7 clean room standards.
  • The company’s business model includes providing stem cell therapies through clinics and selling biologic products to other regenerative healthcare facilities in the U.S.
  • The company also has a supplement division, holding an 18% equity stake in Cement Factory, LLC, focusing on organic supplements sold direct-to-consumer.
  • The stem cell therapy market is described as rapidly expanding, with the global Hematopoietic Stem Cell Transplantation market valued at approximately $3.74 billion in 2025 and growing.
  • The company reported Q3 2026 financials with revenue of $454,385, a net loss of $53,015, cash and equivalents of $1,137,818, current assets of $1,563,614, current liabilities of $1,435,245, a current ratio of 1.09, and a cash ratio of 0.79 as of September 30, 2026.
  • The company’s governance includes a custodian appointed in 2022 with authority to act on behalf of the company, including issuing shares and entering contracts.
  • The company’s regulatory environment involves compliance with FDA regulations under Section 361 of the PHSA and state regulations, with easing regulatory conditions in Florida facilitating operations.
  • The company has filed one provisional patent during 2025 and has trademarked two products: AdiaVita and AdiaLink.
  • The company’s products undergo donor qualification, screening for infectious diseases, and third-party lab certification for sterility and quality.
  • The company’s revenue streams include services from clinics, product sales, and efforts to standardize stem cell protocols with FDA-approved labs.
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-16 | www.nasdaq.com | This Is a Huge Week for the Stock Market: Nvidia Earnings, Fed Minutes, and Anthropic’s IPO | https://www.nasdaq.com/articles/huge-week-stock-market-nvidia-earnings-fed-minutes-and-anthropics-ipo
  • N2 | 2026-11-16 | www.nasdaq.com | TOMI Environmental (TOMZ) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/tomi-environmental-tomz-q3-2026-earnings-call-transcript
  • N3 | 2026-11-16 | www.nasdaq.com | Corn Posting Midday Gains | https://www.nasdaq.com/articles/corn-posting-midday-gains-0
  • N4 | 2026-11-16 | www.nasdaq.com | Millicom International Cellular S.A. Signs Agreement to Acquire Entel Peru for US$1,714 Million | https://www.nasdaq.com/articles/millicom-international-cellular-sa-signs-agreement-acquire-entel-peru-us-1714-million
  • N5 | 2026-11-16 | www.nasdaq.com | IX Acquisition Corp. Enters Amendment No. 5 to Merger Agreement with AERKOMM Inc. | https://www.nasdaq.com/articles/ix-acquisition-corp-enters-amendment-no-5-merger-agreement-aerkomm-inc
  • N6 | 2026-11-16 | www.nasdaq.com | The Bank of N.T. Butterfield & Son Limited Furnishes CIBC Caribbean Financials Ahead of $1,794 million Acquisition | https://www.nasdaq.com/articles/bank-nt-butterfield-son-limited-furnishes-cibc-caribbean-financials-ahead-1794-million
  • N7 | 2026-11-16 | www.nasdaq.com | Virtuix (VTIX) Q2 2027 Earnings Call Transcript | https://www.nasdaq.com/articles/virtuix-vtix-q2-2027-earnings-call-transcript
  • N8 | 2026-11-16 | www.nasdaq.com | GameSquare Holdings (GAME) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/gamesquare-holdings-game-q3-2026-earnings-call-transcript
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine